Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rifapentine

B Jarvis1, H M Lamb

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 7, 1998
PubMed
Summary
This summary is machine-generated.

Rifapentine shows similar tuberculosis treatment success to rifampicin but may have higher relapse rates if compliance is poor. Both antibiotics can cause adverse events like elevated liver enzymes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2015
Same author

Application of Illumina next-generation sequencing to characterize the bacterial community of the Upper Mississippi River.

Journal of applied microbiology·2013
Same author

Stachybotrys: An unusual mold associated with water-damaged buildings.

Mycotoxin research·2013
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2010
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Rifapentine is a rifamycin antibiotic with antimycobacterial properties.
  • It is generally more potent against Mycobacterium tuberculosis than rifampicin, though cross-resistance is common.
  • Previous studies have yielded mixed results regarding efficacy and relapse rates.

Purpose of the Study:

  • To compare the efficacy and safety of rifapentine-based versus rifampicin-based tuberculosis treatment regimens.
  • To investigate the impact of drug compliance on treatment outcomes.
  • To evaluate adverse events associated with both antibiotic regimens.

Main Methods:

  • Review of randomized clinical trials comparing rifapentine and rifampicin for tuberculosis treatment.

Related Experiment Videos

  • Analysis of sputum culture conversion rates and relapse rates.
  • Assessment of treatment-related adverse events, including hyperuricaemia, elevated liver enzymes (ALT/AST), and neutropenia.

    • Main Results:

    • A Western study showed slightly higher sputum culture conversion with rifapentine but also higher relapse rates, potentially linked to poor compliance.
    • Two randomized trials in China demonstrated similar sputum culture conversion rates and low relapse rates for both rifapentine- and rifampicin-containing regimens.
    • Adverse events like hyperuricaemia, elevated ALT/AST, and neutropenia were reported for both regimens, primarily during the intensive phase.

    Conclusions:

    • Rifapentine efficacy is comparable to rifampicin in treating tuberculosis, particularly in Chinese populations.
    • Patient compliance with non-rifamycin drugs is crucial for preventing relapses with rifapentine-based therapy.
    • Both rifapentine and rifampicin share similar safety profiles with manageable adverse events.